Baader Bank Aktiengesellschaft’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,265	Closed	-$283	–	535
2025 Q1	$283	Buy	15,265 +4,439	+41%	+$757	﹤0.01%	421
2024 Q4	$1.56K	Buy	+10,826	New	+$2.13K	﹤0.01%	380

Baader Bank Aktiengesellschaft's VIRX Position: Q2 2025 in Review

Baader Bank Aktiengesellschaft sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 15,265 shares — an estimated $283 sold.

Baader Bank Aktiengesellschaft first reported a position in VIRX in Q4 2024 and held it in 2 quarters. The position peaked at $1.56K in Q4 2024. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.

Baader Bank Aktiengesellschaft reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 15,265 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $283.
Baader Bank Aktiengesellschaft first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2024 and held it in 2 quarters.
Baader Bank Aktiengesellschaft's Viracta Therapeutics, Inc. Common Stock position peaked at $1.56K in Q4 2024.
0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2025, filed 10 Jul 2025.